What are the top healthcare AI agent startups by total funding raised?

Top startups in the healthcare AI agents market ranked by total funding raised

Here is the current ranking of the healthcare AI agents startups that raised the most, with the total each one has raised and our confidence level.

If you want to go deeper into the healthcare AI agents startup landscape, check our report covering the healthcare AI agents market.

1. Minimum: excludes an undisclosed June 2026 strategic investment.
2. Minimum: a further strategic investment has no public amount.
3. Excludes a $240M non-equity growth financing facility.

Why has Abridge raised more than any other healthcare AI agent startup?

Abridge leads healthcare AI agent fundraising with at least $753M raised, thanks to repeated large rounds and broad hospital adoption.

We count 7 equity rounds for Abridge, the most in this market. Its $300M Series D+ in June 2025 was the largest individual round among the companies we track. The money came over several years as Abridge moved from clinical notes toward more of the work surrounding a patient visit.

Abridge said in June 2025 that it worked with more than 150 enterprise health systems. In August 2026, it reported that more than 300 health systems had adopted its newer context-aware clinical decision-support product. The two counts cover different offerings, but the newer launch gives investors another test of how broadly Abridge can sell. Neither number tells us whether those deployments are profitable.

Did one giant round make Abridge the best-funded healthcare AI startup?

No, Abridge's funding lead in healthcare AI took several rounds to build.

Abridge's $150M Series C in February 2024 was the largest healthcare AI agent round recorded that year. The $300M Series D+ in June 2025 then set a new high. Its last recorded financing is an undisclosed-stage round in June 2026 with an undisclosed amount, which makes the cumulative total a minimum.

The contrast is clear with newer entrants. Latent Health has raised $80M in 1 recorded round, and Arbiter has raised $52M in 1 Seed round. Their starting positions are very different from a company that has sold into hospital systems and returned to investors repeatedly.

Is Hippocratic AI closing the funding gap with Abridge?

No, Hippocratic AI remains the second-best-funded healthcare AI agent startup at $402M, behind Abridge.

Hippocratic AI raised a $126M Series C in November 2025 for agents that call patients, coordinate follow-up, and help manage care outside the examination room. Its business depends on executing many routine conversations safely, with appropriate clinical supervision.

WellSpan Health said in July 2026 that its jointly developed Ana agent handled more than 160,000 calls per month. Hippocratic AI also introduced a system for coordinating specialized agents in August 2026. Those are concrete signs of use, but the company's total equity funding remains below Abridge's. Investors are backing a different way to automate care, not a rival medical scribe.

Is Ambience Healthcare still just an AI medical scribe?

No, Ambience Healthcare has raised at least $313M to turn clinical conversations into notes, codes, and other work hospitals need to complete.

Ambience Healthcare's $243M Series C in July 2025 backed a product that joins documentation with clinical coding and record review. Coding matters to hospitals because a correct note must also support the claim and the care actually delivered.

Cleveland Clinic began rolling out the platform in February 2025. A KLAS Research evaluation at Memorial Hermann, published in November 2026, described gains in documentation and emergency-department work. We would still want to see those results repeated across other hospitals. But the deployments show why Ambience can compete for major rounds with companies that started earlier.

Is Suki still attracting major investment in healthcare AI?

Yes, Suki raised a $90M Series D+ in October 2026 and has now raised $255M for clinical AI agents.

Suki began with documentation and has moved into reasoning, reimbursement, and other clinical workflows. It sells an application used by clinicians and also lets healthcare software companies embed its tools. That second route could help it reach more users without selling every hospital system directly.

In its October 2026 announcement, Suki reported relationships with more than 450 healthcare organizations and more than 30 technology partners. The fresh funding backs a platform already distributed through several channels. Investors are testing whether that reach will turn a useful clinical assistant into software that other healthcare products rely on.

Can patient scheduling AI startups really raise hundreds of millions?

Assort Health has raised $222M, putting patient scheduling and access among the biggest healthcare AI agent funding opportunities.

Its $120M Series C in June 2026 backed agents that handle appointments, intake, referrals, patient requests, and parts of the payment process. These tasks are easy for a clinic to recognize: phones go unanswered, appointments get missed, and staff must move information between disconnected systems.

Assort Health announced several senior commercial hires in July 2026 as it prepared for larger deployments. That expansion comes with hard implementation work, particularly live scheduling, patient records, and cases that must be handed to staff. For investors, it offers a business built around completed bookings and resolved patient requests.

Why is automated healthcare billing attracting so much funding?

Candid Health has raised $202M because its healthcare AI agents work on claims and billing, where providers can directly measure results.

The company's $120M Series D+ in July 2026 was led by Sixth Street Growth. Candid automates tasks that practices typically handle with billing employees or outside contractors. Providers can track denied claims, time to payment, and how often staff must step in to fix a bill.

Candid said in its July announcement that annual recurring revenue had grown by 190% year over year. That is a company-reported figure, but it gives investors a much clearer commercial test than an impressive chatbot demonstration. Abridge captures information during a visit, Ambience turns it into structured documentation, and Candid helps providers collect payment for the work.

Are medication-access AI agents now getting major funding?

Yes, Forus has raised at least $275M, including a $150M Series C in September 2026, which puts it fourth in healthcare AI agent fundraising.

Forus coordinates the steps after a doctor writes a prescription. Its network connects prescribers, pharmacies, insurers, and drug manufacturers to handle approvals, coverage, financial assistance, and treatment access. The company is targeting the paperwork and handoffs that can stop a patient from getting prescribed medicine. Both of its large rounds came in 2026, a Series B in May and the Series C four months later, which is why it moved ahead of Suki and Assort Health so quickly.

Latent Health has raised $80M, all of it in a Series A in March 2026, to move medication authorizations through clinical workflows. These businesses show a separate market from documentation: the patient may already have a diagnosis and prescription, yet still need an agent to make treatment happen.

Can European healthcare AI startups raise $100M rounds?

Yes, Sweden's Tandem Health raised a $100M Series B in September 2026 for its clinical documentation and workflow platform.

Tandem Health has raised $163M in total and plans to extend its assistant into a wider clinic operating system. It must work across healthcare markets with different languages, purchasing processes, and rules. That makes a pan-European rollout harder than selling a single English-language tool.

France's Nabla has raised $94M, while Denmark's Corti has raised at least $87M. Australia's Heidi Health offers another international comparison, with a $100M Series C in September 2026. American companies still occupy the top fundraising positions, but foreign founders have shown that large investors will fund clinical AI outside the US.

Why has Tennr raised so much to automate referrals?

Tennr has raised $156M because its healthcare AI agents help patients reach specialists after a referral, a step where paperwork often stalls care.

Tennr's $101M Series C in June 2025 was led by IVP. The software reads referral documents, checks for missing details, and moves patients through the administrative steps needed to book specialty care. A referral can fail even when a clinician made the correct diagnosis, simply because documents never arrive or a form is incomplete.

In a June 2025 Fortune interview, Tennr described rapid revenue growth since its previous round and explained why it trains models on difficult healthcare documents. The company's narrow focus makes its results easier to test: how many referrals turn into real appointments, and how much staff work disappears?

Is Luma Health still a major patient-access AI startup?

Yes, Luma Health has raised $152M for healthcare access and engagement, although its last recorded round was in November 2021.

Its $130M Series C in November 2021 financed scheduling, communication, intake, and reminders before today's wave of generative AI agents. Healthcare organizations were already paying to remove work from reception desks and patient call centers.

Luma's older funding remains relevant to a lifetime equity comparison. Newer funding at Suki and Assort Health tells us where investors have recently put fresh money. Luma shows how long the underlying administrative demand has existed. Those are different questions, and its historical rounds belong in the cumulative total.

Are medical scribes the only healthcare AI startups raising $100M?

No, healthcare AI agent startups have secured major rounds for medication access, billing, scheduling, and referrals as well as clinical documentation.

Forus and Candid Health work on what happens after care is prescribed or delivered. Assort Health handles getting patients into an appointment, and Tennr helps complete specialist referrals. These products give customers a way to count finished tasks, bookings, and claims. Their large rounds show that investors have moved beyond the doctor's note.

Other well-funded businesses work further from the exam room. Medallion has raised at least $128M to automate provider credentialing, Notable has raised $114M for administrative workflows, and Artera.io has raised $110M for patient communication. Their totals cover multiple rounds and should not be mistaken for the size of a single check.

The table below shows selected large rounds across different healthcare AI agent functions.

Company	Round	Amount	Date
Abridge	Series D+	$300M	June 2025
Ambience Healthcare	Series C	$243M	July 2025
Forus	Series C	$150M	September 2026
Luma Health	Series C	$130M	November 2021
Assort Health	Series C	$120M	June 2026
Candid Health	Series D+	$120M	July 2026
Tennr	Series C	$101M	June 2025
Tandem Health	Series B	$100M	September 2026
Heidi Health	Series C	$100M	September 2026

Are investors backing AI agents that actually run pharmacy tasks?

Yes, TJM Labs has raised $85M and Plenful has raised $76M for pharmacy workflow automation.

TJM Labs raised a $75M Series B in July 2026. Its software handles prescription intake, refills, authorization support, and patient communication. The company's announcement described pharmacy acquisitions and a live network of locations, meaning the agents must function inside real pharmacy operations.

Plenful works on repeated administrative tasks across pharmacy teams. Both need to connect with established systems while respecting medical privacy and human checks. Reliable integration can take longer than a demonstration, but it also gives customers a practical reason to keep using the software.

Can health-insurance AI agents attract serious funding?

Health-insurance AI agents do attract serious money: Cohere Health has raised $140M for healthcare authorization workflows, while Alaffia Health and Anterior have also secured substantial backing.

Cohere Health completed a $90M Series C in May 2025 to expand AI tools for clinical authorizations and related decisions. Alaffia Health has raised $70M, including a $55M Series B in February 2026, for claims review. Anterior has raised $63M for insurance administration agents.

These systems operate close to decisions about whether a service is approved or paid. Insurers and providers need clear records of each action and ways for people to review disputed cases. That makes accuracy and accountability essential buying criteria, along with the time saved on manual reviews.

How rare is a healthcare AI agent startup with $100M raised?

Very rare: only 18 healthcare AI agent startups have raised over $100M, and just 1 has passed $500M.

The other 185 of the 203 startups we track sit below $100M in lifetime equity funding, or 91% of the group. The median recorded amount is at least $16M.

Abridge sells across large health systems and has funded years of product and integration work. Smaller companies can start by automating one particular call, pharmacy task, or coding step. The numbers describe differences between companies, not the share of all venture dollars held by each group.

Which leading healthcare AI agent startups are still raising today?

Forus, Suki, Heidi Health, Tandem Health, Assort Health, and Candid Health have recently raised major equity rounds in healthcare AI agents.

Suki's $90M Series D+ in October 2026 financed a broader clinical agent platform, a month after Forus raised its $150M Series C. Heidi Health and Tandem Health both completed large rounds in September 2026, while Assort Health and Candid Health raised again earlier in the year. The buyers and tasks differ, but investors are financing wider installations of products that hospitals and clinics have begun to use.

Luma Health and Notable are still sizable lifetime fundraisers even though their latest recorded financing dates to November 2021. Their older rounds say little about current demand. Recent checks give a more immediate view of which businesses investors are backing now.

Can behavioral health AI startups match hospital AI fundraising?

Not yet, although behavioral health AI agents have attracted sizable funding of their own.

Eleos Health has raised $100M, including a $60M Series C in January 2025. Its product is built for behavioral health documentation and workflows, which differ from those in general hospitals. Denmark's Corti has raised at least $87M for clinical conversational AI infrastructure.

STAT reported in January 2025 that Eleos deliberately focused on behavioral health. That specialization gives the company a chance to fit how therapists and community providers work, even if its total funding remains below general hospital documentation leaders. Whether that becomes a larger business will depend on repeated deployments and customers continuing to pay.

Are the best-funded healthcare AI agents mostly American?

Yes, US startups occupy the top of the healthcare AI agent fundraising list, and 157 of the 203 startups in this market are American.

US startups make up 77% of a group spread across 21 countries. Abridge, Hippocratic AI, and Ambience Healthcare lead the cumulative funding comparison, with Forus, Suki, Assort Health, and Candid Health also based in the US. The country's complex billing, insurance, and hospital administration creates many tasks that software can automate.

Heidi Health in Australia and Tandem Health in Sweden show that the market extends beyond America. France's Nabla and Denmark's Corti also target clinical workflows. The country table below counts startups, not dollars.

The table below shows the countries with the largest numbers of healthcare AI agent startups in our fundraising comparison.

Country	Startups
United States	157
United Kingdom	7
France	6
Australia	4
Brazil	4
Belgium	3
Germany	3
Israel	3

Do healthcare AI agent startups get acquired before raising $100M?

Yes, healthcare AI agent startups can be acquired well before they raise the amounts associated with the market's biggest companies.

We count 9 acquired companies in the fundraising comparison. Pieces Technologies raised $87M before acquisition, SmarterDx raised $50M, and Memora Health raised at least $30M. Each worked on clinical or administrative processes that larger healthcare technology companies can incorporate into existing products.

Acquisition changes who owns the product, but it does not change the equity the original startup raised. We count its financing history only up to the acquisition. The examples show that building something useful enough to buy need not require leading the lifetime fundraising ranking.

So, which healthcare AI agent startups have raised the most money?

Abridge is the top healthcare AI agent startup by cumulative funding, with Hippocratic AI, Ambience Healthcare, and Forus next.

Abridge built its lead through successive rounds and large hospital relationships. Hippocratic AI has raised money for patient-facing agents, while Ambience Healthcare combines documentation with coding. Forus has raised at least $275M for medication access. Suki, Assort Health, and Candid Health show how widely investors are spreading their bets across clinical tasks, scheduling, and billing.

The table below shows what we found.

Question	Answer
Who has built the deepest funding lead?	Abridge is the clear cumulative funding leader among healthcare AI startups. It has raised at least $753M across successive equity rounds. That history reflects repeated investor backing as its hospital footprint expanded.
Can voice agents compete with clinical scribes?	Yes, patient-facing systems have become major venture-funded healthcare businesses. Hippocratic AI has raised $402M for its agent platform. Its WellSpan partnership shows why large patient communication workloads matter.
Has coding become central to documentation funding?	Yes, documentation businesses increasingly connect clinical notes with reimbursement. Ambience Healthcare has raised at least $313M for that platform. Hospital deployments give investors a broader financial case than transcription alone.
Are mature clinical assistants still attracting cash?	They are, and established products continue adding more autonomous functions. Suki's October 2026 Series D+ brought in $90M. Its expansion beyond notes supports a wider enterprise software pitch.
Can patient scheduling attract top-tier venture checks?	Yes, patient access is a major healthcare automation purchasing need. Assort Health's June 2026 Series C raised $120M. That capital backs scheduling and intake workflows beyond the physician encounter.
Is autonomous billing attracting large late-stage capital?	Yes, investors see providers' reimbursement work as an automation opportunity. Candid Health's July 2026 Series D+ raised $120M. Faster, more accurate claims offer a measurable case for adoption.
Can healthcare AI succeed outside American hospitals?	Yes, sizable financing also reaches companies built in other countries. Tandem Health's September 2026 Series B raised $100M. Its European deployments require navigating multiple healthcare procurement and regulatory environments.
Did referral automation become a major category?	Yes, specialized handoffs can justify unusually large venture rounds. Tennr's June 2025 Series C raised $101M in venture funding. Processing referrals helps patients reach specialists after a doctor recommends care.
Are most healthcare agent startups already heavily funded?	No, the most visible companies are unusual rather than typical. We track 185 startups below $100M in cumulative funding. The long tail means useful automation can start with smaller financing.
Do acquisitions erase money raised before a sale?	No, acquisition changes ownership rather than the startup's historical financing. We count 9 acquired businesses in this market. Their funding histories remain relevant when comparing how products were built.